InspireMD, Inc.
NSPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.12 | -0.19 | -0.19 |
| FCF Yield | -5.06% | -7.69% | -6.80% | -5.49% |
| EV / EBITDA | -8.96 | -8.34 | -10.95 | -12.05 |
| Quality | ||||
| ROIC | -19.29% | -51.68% | -35.83% | -23.76% |
| Gross Margin | 34.24% | 17.60% | 19.10% | 24.06% |
| Cash Conversion Ratio | 0.68 | 0.63 | 0.79 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.46% | 9.75% | 10.37% | 10.67% |
| Free Cash Flow Growth | -0.59% | 2.64% | -29.60% | -15.36% |
| Safety | ||||
| Net Debt / EBITDA | 4.72 | 0.63 | 0.89 | 1.78 |
| Interest Coverage | 0.00 | -98.63 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.46 | 0.48 | 0.44 | 0.58 |
| Cash Conversion Cycle | 170.53 | 200.05 | 217.58 | 184.11 |